超200亿，海归博士收获一个IPO

Core Viewpoint - North Chip Life successfully listed on the A-share market, becoming the first medical device company to do so under the fifth standard of the Science and Technology Innovation Board, with a market value exceeding 20 billion yuan shortly after its IPO [4][21]. Company Overview - Founded by overseas PhD Song Liang in 2015, North Chip Life focuses on coronary artery disease, peripheral vascular disease, and atrial fibrillation, aiming to reduce reliance on imported products in China [5][10]. - The company has developed China's first domestically approved 60MHz high-definition intravascular ultrasound (IVUS) product and the first domestically approved FFR measurement system, filling significant gaps in the market [10][12]. Market Performance - North Chip Life's IVUS system achieved the highest market share among domestic products, while its FFR system captured 30.6% of the domestic market within a year of launch [12][16]. - The company reported revenues of approximately 92 million yuan in 2022, growing to about 184 million yuan in 2023, and projected to reach around 317 million yuan in 2024, maintaining a gross margin above 63% [16]. Investment and Support - The company has received substantial backing from various investors, including Sequoia China and Qiming Venture Partners, which have supported multiple funding rounds [7][18]. - The long-term support from investors has been crucial for North Chip Life's development, allowing it to navigate the high-risk, high-investment landscape of innovative medical device development [19][20]. Product Development - North Chip Life has launched 11 products to date, with 6 more in development, covering five major product categories including IVUS systems and FFR systems [15]. - The company emphasizes the importance of understanding clinical needs and market demands in its product innovation strategy, leading to significant breakthroughs in technology [11][16].